ATB-346, being developed by Antibe Therapeutics, a Toronto-based pharmaceutical company, is a hydrogen sulfide-releasing non-steroidal anti-inflammatory drug (NSAID) that inhibits COX and suppresses prostaglandin production. ATB-346 exhibits anti-inflammatory, analgesic, antinociceptive, immunomodulatory, and neuroprotective activities. In vivo, this compound attenuates zymosan-induced inflammation, nociception, and immune signaling. ATB-346 also prevents ligature-induced periodontal bone loss and pathologies, potentially by suppressing increases in pro-inflammatory cytokine levels. Additionally, ATB-346 decreases edema and improves neurological function in animal models of traumatic brain injury (TBI). ATB-346 completed Phase 1 clinical studies in Q1 2015. To better understand the metabolism of ATB-346, Antibe conducted a radiolabeled study in rats at Covance Laboratories that was completed in Q4 2015. Antibe received approval from Health Canada in March 2016 to conduct a Phase 2 trial of ATB-346 in patients with osteoarthritis of the knee. Preclinical studies of ATB-346 for the treatment intestinal cancer; malignant melanoma; periodontal disorders are in progress.